Furthermore, we have previously monitored sHER2 in 12 patients with DCIS who had received dendritic cell-based vaccines against HER2 peptide prior to their definitive surgery (Lam et al. 2014). The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.